Scott Sandell Net Worth & Insider Trades

Scott Sandell Regulus Therapeutics Inc

As of March 16, 2021

What is Scott Sandell's Net Worth?

The current estimated net worth of Regulus Therapeutics Inc's Scott Sandell is estimated to be about $2.87B . Scott Sandell owns about 6,451,056 units of Regulus Therapeutics Inc common stock. In the last 2 years at Regulus Therapeutics Inc, Scott Sandell has sold an estimated value of $0 worth.

What is Scott Sandell's Past Insider Trading?

Scott Sandell's largest purchase order was 4,398,602 units , worth over $2.74M on December 7, 2020. In total, Scott Sandell has made about 4 transactions over 2 years of their time at Regulus Therapeutics Inc. Scott Sandell usually trades in December, with the busiest year in 2019.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

SCOTT SANDELL

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What are Regulus Therapeutics Inc's Past Insider Trades?

Regulus Therapeutics Inc's most recent insider trade came on March 1, 2022 by Denis Drygin who bought 76,686 units worth $17.64K . In the last 10 years, insiders at Regulus Therapeutics Inc have sold an estimated value of $79.77M and bought an estimated value of $68.89M worth of shares. Insider trading is most common in June, with the busiest year in 2019. The most active traders at the company are Joseph Hagan, President and CEO,  Stelios Papadopoulos, Director,  and Christopher Aker, Sr. VP & General Counsel .

Regulus Therapeutics Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...